Plato Investment Management’s AbbVie ABBV Stock Holding History

Plato Investment Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$12.3M	Buy	56,432 +5,811	+11%	+$1.29M	0.82%	16
2025 Q4	$11.6M	Sell	50,621 -2,858	-5%	-$651K	0.76%	15
2025 Q3	$12.3M	Buy	53,479 +1,325	+3%	+$270K	0.83%	15
2025 Q2	$9.65M	Buy	52,154 +410	+0.8%	+$76.2K	0.73%	20
2025 Q1	$11M	Sell	51,744 -13,721	-21%	-$2.67M	0.92%	16
2024 Q4	$11.7M	Buy	65,465 +4,901	+8%	+$901K	0.86%	14
2024 Q3	$11.9M	Buy	60,564 +930	+2%	+$174K	0.97%	12
2024 Q2	$10.2M	Buy	59,634 +4,195	+8%	+$695K	0.95%	15
2024 Q1	$10.1M	Buy	55,439 +47,466	+595%	+$8.18M	1.04%	12
2023 Q4	$1.24M	Buy	+7,973	New	+$1.16M	1.52%	10

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Plato Investment Management's ABBV Position: Q1 2026 in Review

Plato Investment Management increased its AbbVie (ABBV) stake by 11% in Q1 2026, buying an estimated $1.29M and bringing the position to 56,432 shares worth $12.3M. The position accounts for 0.82% of the portfolio, ranked #16.

Plato Investment Management first reported a position in ABBV in Q4 2023 and has held it in 10 quarters since. The position peaked at $12.3M in Q3 2025. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Plato Investment Management held 56,432 shares of AbbVie worth $12.3M as of Q1 2026.
Plato Investment Management bought 5,811 AbbVie shares in Q1 2026, an estimated $1.29M.
AbbVie made up 0.82% of Plato Investment Management's portfolio in Q1 2026, its #16 holding.
Plato Investment Management first reported a position in AbbVie in Q4 2023 and has held it in 10 quarters since.
Plato Investment Management's AbbVie position peaked at $12.3M in Q3 2025.
4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Plato Investment Management's 13F filing for Q1 2026, filed 5 May 2026.